[⁶⁴Cu]Cu-NOTA-Trastuzumab and [⁸⁹Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression.

ABSTRACT: Positron emission tomography (PET) has potential as a complementary technique to biomarker analysis, especially for human epidermal growth factor receptor 2 (HER2)-expressing tumors characterized by high heterogeneity. In this study, zirconium-89 (⁸⁹Zr) and copper-64 (⁶⁴Cu) labeled trastuzumab were employed to monitor varying levels of tumoral HER2 expression. Additionally, we studied the use of the cholesterol-depleting lovastatin as a pharmacological approach to enhance cell-surface HER2 expression in tumors with moderate to low HER2 levels, aiming to increase antibody accumulation in these tumor types. Both ⁸⁹Zr- and ⁶⁴Cu-labeled trastuzumab effectively monitor HER2 expression levels in xenografts exhibiting varying HER2 expression. No signifi

SUBMITTER: Simo C 

PROVIDER: S-EPMC11611601 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature